Fresenius reported sales +7% (+6% at cc) to €7,738m and the gross profit margin improved by 40bp to 32.0% in Q4. EBITDA clearly increased +15% to €1,544m and net profit attributable to shareholders went up +22% to €439m. Operating CF rose +12% to €1,315m reflecting the strong operating performance and a lower, but still suitable, NWC inflow (€185m after €238m). Investing CF moved from €-499m to €-732m, pushed downwards by a swing from net divestment pro
23 Feb 2017
No prolongation for Kabi, but Helios on the move in 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No prolongation for Kabi, but Helios on the move in 2017
Fresenius SE & Co. KGaA (FRE:WBO) | 0 0 0.5% | Mkt Cap: 35,173m
- Published:
23 Feb 2017 -
Author:
Martin Schnee -
Pages:
3
Fresenius reported sales +7% (+6% at cc) to €7,738m and the gross profit margin improved by 40bp to 32.0% in Q4. EBITDA clearly increased +15% to €1,544m and net profit attributable to shareholders went up +22% to €439m. Operating CF rose +12% to €1,315m reflecting the strong operating performance and a lower, but still suitable, NWC inflow (€185m after €238m). Investing CF moved from €-499m to €-732m, pushed downwards by a swing from net divestment pro